Our previous 16 regular issues of Life Science Leader (excluding the annual outlook issue) featured a biopharmaceutical company CEO on the cover. But our cover features aren’t limited to the CEO, as this month’s issue shows with our feature on J&J’s CFO, Joe Wolk.
Together we can go further and faster to address issues of equity, diversity, and inclusion (ED&I). As our industry embarks on this shared journey, I’d like to suggest three practical approaches that every leader can incorporate into their ED&I strategy to initiate meaningful change.
In this executive virtual roundtable segment, Edith Perez, M.D., chief medical officer at Bolt Biotherapeutics, an immuno-oncology company, discusses how she became involved in various diversity and inclusion initiatives.
The lack of diversity in clinical trials isn’t a new problem, but in 2020 this issue rose to the forefront of the industry as a spotlight was cast on drug development as a whole due to the COVID-19 pandemic.